Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer

NCT06930755 is registered in ClinicalTrials.gov with Nerviano Medical Sciences as lead sponsor.

NCT NCT06930755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06930755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer
Lead sponsor
Nerviano Medical Sciences
Phase
Phase 1
Overall status
Recruiting
Start date
May 13, 2026
Completion date
September 26, 2027
Enrollment
24 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer